Health insurance companies are now no longer immune from antitrust scrutiny for activities previously found to be “the business of insurance.” Last week, the Competitive Health Insurance Reform Act (CHIRA) was enacted, repealing health insurers’ federal antitrust immunity provided by the McCarran-Ferguson Act. Prior to CHIRA, insurers were immune from federal antitrust liability for all conduct that (1) was part of the business of insurance, (2) was regulated by state law, and (3) did not constitute a boycott, coercion, or intimidation.1 Courts had exempted insurers from federal antitrust liability — even when state law was deemed to ineffectively regulate the business of insurance.2
With the enactment of CHIRA, the U.S. Department of Justice and Federal Trade Commission have expanded authority and oversight to regulate the business of health insurance and prosecute allegedly anticompetitive behavior. The repeal of the exemption potentially exposes insurers to federal antitrust liability for any alleged collaborative or anticompetitive conduct, including, but not limited to:
-
Agreements regarding data sharing between insurers;
-
Cooperative ratemaking among insurers;3
-
Form standardization;
-
Joint underwriting;4
-
Claims handling;5
-
Reinsurance risk spreading;6 and
-
Any other conduct that would ordinarily give rise to a federal antitrust cause of action for which the McCarran-Ferguson Act previously afforded immunity including under the Clayton Act, the Sherman Act, and FTC Act.7
Advocates for the repeal of the McCarran-Ferguson exception cite CHIRA as beneficial for insurance competition and protecting consumers within the health insurance.8 Experienced counsel can assist in navigating the newly heightened regulation and potential antitrust liabilities insurers are now exposed to with the repeal of the McCarren-Ferguson exemption.